Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

You may be eligible if

• Histologically confirmed advanced solid tumor cancer for which no curativetherapy exists
• Clinically stable CNS disease is allowed provided the following criteria are met:
• * No uncontrolled brain metastases or CNS involvement
• * No active seizures
• * On stable dose of antiseizure or steroid medication for at least 7 days before study enrollment
• Performance status - ECOG 0-2
• At least 12 weeks
• Absolute neutrophil count at least 1,500/mm\^3
• Hemoglobin at least 9 g/dL
• Platelet count at least 100,000/mm\^3
• Bilirubin no greater than 1.5 mg/dL
• AST/ALT no greater than 2.5 times upper limit of normal
• Creatinine no greater than 1.5 mg/dL
• Creatinine clearance at least 60 mL/min
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No active infection
• No other serious concurrent systemic disorders (including other malignancy)
• No prior bone marrow or peripheral blood stem cell transplantation
• No concurrent immunotherapy
• See Disease Characteristics
• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
• Prior carboplatin and/or etoposide allowed
• No more than 2 prior courses of mitomycin
• See Disease Characteristics
• No concurrent hormonal therapy
• At least 4 weeks since prior radiotherapy and recovered
• Palliative radiotherapy involving less than 35% bone marrow reserve allowed if completed at least 2 weeks before study enrollment
• No prior wide-field radiotherapy to 35% or more of bone marrow
• No prior pelvic radiotherapy
• No concurrent radiotherapy
• At least 28 days since prior investigational agents
• No other concurrent experimental medications